Nidan Laboratories & Healthcare Ltd
Incorporated in 2000, Nidan Laboratories & Healthcare Ltd is in the business of providing various Healthcare and Diagnostics Services[1]
- Market Cap ₹ 19.3 Cr.
- Current Price ₹ 13.9
- High / Low ₹ 24.9 / 12.8
- Stock P/E 11.0
- Book Value ₹ 50.1
- Dividend Yield 0.00 %
- ROCE 5.99 %
- ROE 2.55 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.28 times its book value
- Company's working capital requirements have reduced from 87.8 days to 33.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 4.62% over past five years.
- Company has a low return on equity of 1.81% over last 3 years.
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 20.07 | 21.41 | 20.38 | 29.66 | 24.27 | 24.18 | 24.53 | 25.54 | |
| 12.23 | 13.78 | 11.49 | 20.25 | 17.47 | 17.74 | 19.47 | 20.70 | |
| Operating Profit | 7.84 | 7.63 | 8.89 | 9.41 | 6.80 | 6.44 | 5.06 | 4.84 |
| OPM % | 39.06% | 35.64% | 43.62% | 31.73% | 28.02% | 26.63% | 20.63% | 18.95% |
| 0.37 | 0.01 | 1.06 | 0.40 | 3.33 | -3.76 | 2.25 | 1.46 | |
| Interest | 4.75 | 3.74 | 3.46 | 2.66 | 2.22 | 2.18 | 2.14 | 1.96 |
| Depreciation | 3.24 | 3.19 | 3.18 | 2.63 | 3.10 | 2.87 | 2.41 | 1.90 |
| Profit before tax | 0.22 | 0.71 | 3.31 | 4.52 | 4.81 | -2.37 | 2.76 | 2.44 |
| Tax % | 0.00% | 0.00% | 30.21% | 41.15% | 26.40% | 36.29% | 28.26% | 38.11% |
| 0.22 | 0.71 | 2.30 | 2.66 | 3.54 | -3.23 | 1.98 | 1.51 | |
| EPS in Rs | 0.22 | 0.72 | 2.32 | 1.91 | 2.55 | -2.32 | 1.42 | 1.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -19% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -33% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.90 | 9.90 | 9.90 | 13.90 | 13.90 | 13.90 | 13.90 | 13.90 |
| Reserves | 0.41 | 1.13 | 3.43 | 52.00 | 55.54 | 52.31 | 54.28 | 55.79 |
| 32.16 | 34.35 | 38.04 | 19.29 | 10.93 | 12.44 | 11.11 | 11.17 | |
| 0.58 | -0.17 | 2.37 | 3.29 | 4.03 | 3.90 | 3.65 | 3.14 | |
| Total Liabilities | 43.05 | 45.21 | 53.74 | 88.48 | 84.40 | 82.55 | 82.94 | 84.00 |
| 23.28 | 20.10 | 19.92 | 20.46 | 21.39 | 17.95 | 16.33 | 14.91 | |
| CWIP | 0.00 | 0.00 | 0.23 | 3.81 | 0.00 | 0.04 | 0.15 | 0.15 |
| Investments | 0.53 | 0.53 | 0.27 | 0.00 | 0.00 | 0.00 | 20.00 | 20.00 |
| 19.24 | 24.58 | 33.32 | 64.21 | 63.01 | 64.56 | 46.46 | 48.94 | |
| Total Assets | 43.05 | 45.21 | 53.74 | 88.48 | 84.40 | 82.55 | 82.94 | 84.00 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 8.95 | 4.62 | 4.35 | 7.83 | 10.97 | 5.52 | 2.28 | 1.67 | |
| 1.00 | -0.01 | -3.22 | -35.74 | -0.29 | -10.60 | -0.22 | 0.06 | |
| -5.81 | -1.56 | -1.22 | 28.72 | -10.37 | -0.49 | -3.01 | -1.63 | |
| Net Cash Flow | 4.14 | 3.05 | -0.10 | 0.80 | 0.32 | -5.57 | -0.95 | 0.10 |
| Free Cash Flow | 9.95 | 4.61 | 1.13 | 1.36 | 11.02 | 4.88 | 1.41 | 1.19 |
| CFO/OP | 114% | 61% | 49% | 96% | 162% | 129% | 77% | 55% |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102.03 | 92.57 | 97.25 | 65.96 | 90.69 | 7.85 | 18.90 | 31.73 |
| Inventory Days | 16.98 | 12.88 | 18.17 | 25.99 | ||||
| Days Payable | 116.72 | -25.76 | 213.05 | 135.84 | ||||
| Cash Conversion Cycle | 2.29 | 131.22 | -97.64 | -43.89 | 90.69 | 7.85 | 18.90 | 31.73 |
| Working Capital Days | 256.25 | 291.69 | -189.31 | 54.52 | 43.46 | 243.18 | -13.39 | 33.58 |
| ROCE % | 10.13% | 13.99% | 10.09% | 8.17% | 7.95% | 6.17% | 5.99% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Trade Receivable Turnover Ratio Ratio |
|
||||
| Number of Permanent Employees Number |
|||||
| Revenue from Pathology Rs. in Lakhs |
|||||
| Revenue from Radiology Rs. in Lakhs |
|||||
| Number of Diagnostic Centers Number |
|||||
Extracted by Screener AI
Documents
Announcements
-
Copy of Newspaper Publication
26 May 2026 - Nidan Laboratories published audited FY26 results; revenue rose to Rs 2,554.16 lakh, PAT Rs 150.60 lakh.
-
Change in Management
25 May 2026 - Board approved FY26 audited results, reappointed two independent directors and statutory auditor for five years.
-
Outcome of Board Meeting
25 May 2026 - Board approved FY26 audited results and reappointed two independent directors and statutory auditor on 25 May 2026.
-
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
29 April 2026 - SEBI issued SCN over alleged misuse of Rs.29.99 crore IPO proceeds and misstatements in FY22-FY23.
-
Structural Digital Database
28 April 2026 - Filed SDD compliance certificate for FY ended 31 March 2026.
Business Overview:[1]
NLHL is a Healthcare Division of Nidan Group. It operates 35 diagnostic centers across Greater Mumbai under the Nidan Diagnostics brand. Services include CT scan, MRI, Ultrasound, 2D Echo, ECG, and more.